News

Company has announced a non-exclusive license agreement with IDT for CRISPR-Cas9 Reagents under Caribou’s intellectual property.

The Genome Analysis Centre (TGAC) hosts a five-day training course on cell signalling; from gene regulation to cellular models, to study signalling networks of plants, microbes and animals.

Grant will fund partnership between Desktop Genetics and Imperial College London to develop and validate software tools to design and test site-specific epigenetic CRISPR systems to target drug resistance mechanisms in cancer cells.

A simple blood test that can accurately diagnose active tuberculosis could make it easier and cheaper to control a disease that kills 1.5 million people every year.

Fresh approach identifies genetic risk factors that influence complex human diseases

Future T cell therapies with less side effects.

Researchers have resolved a mystery about how a promising new class of anti-cancer drugs, called nutlins, work - paving the way for improving the future of cancer treatment.

Company has announced that its synthetic vaccine for Zika virus induces immune responses, demonstrating its potential to prevent and treat infections from this harmful pathogen.

Company has announced the collaboration for development of clinical tests utilizing high-throughput Next Generation Sequencing capabilities.

New mathematical model explains variability in mutation rates across the human genome.